نتائج البحث - "Diabetic Nephropathies drug therapy"

المصدر: Heerspink, H J L, Xie, D, Bakris, G, Correa-Rotter, R, Hou, F F, Kitzman, D W, Kohan, D, Makino, H, McMurray, J J V, Perkovic, V, Rossing, P, Parving, H H & de Zeeuw, D 2021, ' Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist : A prespecified analysis from the SONAR trial ', Journal of the American Society of Nephrology, vol. 32, no. 11 . https://doi.org/10.1681/ASN.2021030391
J Am Soc Nephrol
Journal of the American Society of Nephrology, 32(11), 2900-2911. AMER SOC NEPHROLOGY

مصطلحات موضوعية: Relative risk reduction, Endothelin Receptor Antagonists, Male, Endothelin receptor antagonist, Type 2 diabetes, Endothelin Receptor Antagonists/therapeutic use, chemistry.chemical_compound, Sodium Potassium Chloride Symporter Inhibitors, Creatinine/urine, Chronic kidney disease, Randomized controlled clinical trial, Diabetic Nephropathies, Renal Insufficiency, General Medicine, Middle Aged, Causality, Treatment Outcome, Nephrology, Creatinine, Combination, Albuminuria/drug therapy, Female, Drug Therapy, Combination, medicine.symptom, medicine.drug, medicine.medical_specialty, Urology, Placebo, Chronic/drug therapy, Drug Therapy, Double-Blind Method, Up Front Matters, medicine, Albuminuria, Humans, Renal Insufficiency, Chronic, Aged, Renal Insufficiency, Chronic/drug therapy, business.industry, Atrasentan, medicine.disease, Personalized medicine, Nephropathy, chemistry, Diabetic Nephropathies/drug therapy, Atrasentan/therapeutic use, business, Sodium Potassium Chloride Symporter Inhibitors/therapeutic use, Risk Reduction Behavior, Kidney disease

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3229bb943a3e125089e6943a22428b7c
https://pure.au.dk/portal/da/publications/early-response-in-albuminuria-and-longterm-kidney-protection-during-treatment-with-an-endothelin-receptor-antagonist(d57ec1ed-ed75-4aa5-8909-6db92797b939).html

4

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

المؤلفون: Niels Jongs, Bergur V. Stefánsson, Ricardo Correa-Rotter, Robert D. Toto, John J.V. McMurray, Tom Greene, Dapa-Ckd Trial Committees, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink, David C. Wheeler, Glenn M. Chertow, Investigators, Peter Rossing

المساهمون: Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Groningen Kidney Center (GKC)

المصدر: Lancet Diabetes & Endocrinology, 9(11), 755-766. ELSEVIER SCIENCE INC

مصطلحات موضوعية: Male, Diabetes Mellitus, Type 2/drug therapy, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Glomerular Filtration Rate/drug effects, Placebos, chemistry.chemical_compound, Endocrinology, Glucosides, Creatinine/urine, Diabetic Nephropathies, Renal Insufficiency, Dapagliflozin, Middle Aged, Type 2/drug therapy, Creatinine, Albuminuria/drug therapy, Female, medicine.symptom, Glomerular Filtration Rate, medicine.medical_specialty, Urology, Renal function, Placebo, Chronic/drug therapy, Double-Blind Method, Diabetes mellitus, Benzhydryl Compounds/therapeutic use, Internal Medicine, medicine, Diabetes Mellitus, Albuminuria, Humans, Renal Insufficiency/prevention & control, Benzhydryl Compounds, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Aged, Renal Insufficiency, Chronic/drug therapy, business.industry, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, medicine.disease, Glucosides/therapeutic use, chemistry, Diabetes Mellitus, Type 2, Diabetic Nephropathies/drug therapy, Microalbuminuria, business, Kidney disease

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89091bdd4249d265893bbdc171c8e7e
https://research.rug.nl/en/publications/c2af467f-022b-4ad1-a4f9-5caab2e93272

View record from ScienceDirect

Full Text via ClinicalKey

5

Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial

المساهمون: Ruggenenti, P., Trillini, M., P. Barlovic, D., Cortinovis, M., Pisani, A., Parvanova, A., Iliev, I. P., Ruggiero, B., Rota, S., Aparicio, M. C., Perna, A., Peraro, F., Diadei, O., Gaspari, F., Carrara, F., Stucchi, N., Martinetti, D., Janez, A., Gregoric, N., Riccio, E., Bossi, A. C., Trevisan, R., Manunta, P., Battaglia, G., David, S., Aucella, F., Belviso, A., Satta, A., Remuzzi, G., Ruggenenti, P, Trillini, M, P. Barlovic, D, Cortinovis, M, Pisani, A, Parvanova, A, Iliev, I, Ruggiero, B, Rota, S, Aparicio, M, Perna, A, Peraro, F, Diadei, O, Gaspari, F, Carrara, F, Stucchi, N, Martinetti, D, Janez, A, Gregoric, N, Riccio, E, Bossi, A, Trevisan, R, Manunta, P, Battaglia, G, David, S, Aucella, F, Belviso, A, Satta, A, Remuzzi, G

المصدر: Diabetes, obesity and metabolism
21 (2019): 1177–1190. doi:10.1111/dom.13639
info:cnr-pdr/source/autori:Piero Ruggenenti; Matias Trillini; Drazenka P. Barlovic; Monica Cortinovis; Antonio Pisani; Aneliya Parvanova; Ilian Iliev; Barbara Ruggiero; Stefano Rota; Maria C Aparicio; Annalisa Perna; Francesco Peraro; Olimpia Diadei; Flavio Gaspari; Fabiola Carrara; Nadia Stucchi; Davide Martinetti; Andrej Janez; Nadah Gregoric; Eleonora Riccio; Antonio C. Bossi; Roberto Trevisan; Paolo Manunta; Giovanni Battaglia; Salvatore David; Filippo Aucella; Antonio Belviso,; Andrea Satta; Giuseppe Remuzzi/titolo:Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial/doi:10.1111%2Fdom.13639/rivista:Diabetes, obesity and metabolism (Print)/anno:2019/pagina_da:1177/pagina_a:1190/intervallo_pagine:1177–1190/volume:21

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Combination therapy, Endocrinology, Diabetes and Metabolism, Slovenia, Urology, Benazepril, Blood Pressure, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Kidney Function Tests, Nephropathy, Diabetic nephropathy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Internal Medicine, medicine, Humans, Diabetic Nephropathies, Aged, type 2 diabete, Creatinine, business.industry, diabetic nephropathy, Benzazepines, Middle Aged, diabetic nephropathy, phase III study, type 2 diabetes, Adult, Aged, Benzazepines, Biomarkers, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Drug Therapy, Combination, Female, Humans, Italy, Kidney Function Tests, Male, Middle Aged, Slovenia, Treatment Outcome, Valsartan, medicine.disease, phase III study, Treatment Outcome, Diabetes Mellitus, Type 2, Italy, chemistry, Valsartan, ACE inhibitor, Drug Therapy, Combination, Female, type 2 diabetes, business, Biomarkers, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0d10aa43a21f6f1dde449b2567a943e
https://doi.org/10.1111/dom.13639

View record at Wiley

6

Inhibiteurs du SGLT2 dans les néphropathies diabétiques et non diabétiques [SGLT2 inhibitors in diabetic and non-diabetic nephropathies]

المؤلفون: Scheen, M., Zanchi, A., Martin, P.Y., De Seigneux, S.

المصدر: Revue medicale suisse, vol. 17, no. 727, pp. 378-382

مصطلحات موضوعية: Diabetes Mellitus, Type 2, Diabetic Nephropathies/drug therapy, Humans, Hypoglycemic Agents/therapeutic use, Sodium-Glucose Transporter 2, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______1900::f31d05ac382b8f7e1794caec01f70ba9
https://serval.unil.ch/notice/serval:BIB_21FE0DE609F2

7

دورية أكاديمية

Inhibiteurs des SGLT2: focus sur le rein et la néphroprotection.
SGLT2 inhibitors: focus on kidneys and nephroprotection

المؤلفون: Scheen, André, Delanaye, Pierre

المصدر: Revue Médicale Suisse, 17 (747), 1397-1403 (2021)

مصطلحات موضوعية: Diabetes Mellitus, Type 2/complications/drug therapy, Diabetic Nephropathies/drug therapy/prevention & control, Glomerular Filtration Rate, Humans, Kidney, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, Human health sciences, Pharmacy, pharmacology & toxicology, Urology & nephrology, Sciences de la santé humaine, Pharmacie, pharmacologie & toxicologie, Urologie & néphrologie

Relation: urn:issn:1660-9379

URL الوصول: https://orbi.uliege.be/handle/2268/264347

8

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

المؤلفون: David C. Wheeler, Tom Greene, John J.V. McMurray, Hiddo J.L. Heerspink, Robert D. Toto, Anna Maria Langkilde, Glenn M. Chertow, Bergur V. Stefánsson, Fan Fan Hou, Ricardo Correa-Rotter, Dapa-Ckd Trial Committees, Investigators, Peter Rossing, C. David Sjöström, Niels Jongs

المساهمون: Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Groningen Kidney Center (GKC)

المصدر: Lancet Diabetes & Endocrinology, 9(1), 22-31. ELSEVIER SCIENCE INC
DAPA-CKD Trial Committees and Investigators 2021, ' Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial ', The Lancet Diabetes and Endocrinology, vol. 9, no. 1, pp. 22-31 . https://doi.org/10.1016/S2213-8587(20)30369-7

مصطلحات موضوعية: Male, Endocrinology, Diabetes and Metabolism, Benzhydryl Compounds/adverse effects, Type 2 diabetes, Kidney/drug effects, Kidney, Kidney Failure, Diabetic nephropathy, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Glucosides, Kidney Failure, Chronic/chemically induced, Diabetic Nephropathies, Renal Insufficiency, 030212 general & internal medicine, Dapagliflozin, Middle Aged, Cardiovascular Diseases/chemically induced, Type 2/complications, Treatment Outcome, Cardiovascular Diseases, Female, Adult, Chronic/complications, medicine.medical_specialty, Renal Insufficiency, Chronic/complications, Renal function, 030209 endocrinology & metabolism, Glucosides/adverse effects, 03 medical and health sciences, Chronic/chemically induced, Double-Blind Method, Diabetes mellitus, Internal medicine, Diabetes Mellitus, Internal Medicine, medicine, Humans, Benzhydryl Compounds, Renal Insufficiency, Chronic, Adverse effect, Heart Failure/chemically induced, Aged, Heart Failure, business.industry, Diabetes Mellitus, Type 2/complications, medicine.disease, Diabetes Mellitus, Type 2, chemistry, Heart failure, Diabetic Nephropathies/drug therapy, Kidney Failure, Chronic, business, Kidney disease

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a3a1159f26d848e4b231091b2729525
https://research.rug.nl/en/publications/92ee2074-5922-4044-aceb-cfcbddfff59c

View record from ScienceDirect

Full Text via ClinicalKey

9

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes

المؤلفون: Oliver Schnell, Pieter Gillard, Per-Henrik Groop

المساهمون: Pathology/molecular and cellular medicine, Diabetes Pathology & Therapy, Diabetes Clinic, HUS Abdominal Center, Research Programs Unit, Department of Medicine, Per Henrik Groop / Principal Investigator, Clinicum, Nefrologian yksikkö, University of Helsinki, Helsinki University Hospital Area, CAMM - Research Program for Clinical and Molecular Metabolism

مصطلحات موضوعية: CHRONIC KIDNEY-DISEASE, Male, Diabetes Mellitus, Type 2/drug therapy, endocrine system diseases, medicine.medical_treatment, Endocrinology, Diabetes and Metabolism, DOUBLE-BLIND, 0302 clinical medicine, Endocrinology, Insulin, SGLT inhibition, Diabetic Nephropathies, 030212 general & internal medicine, Body mass index, METABOLIC SYNDROME, RISK, COMPLICATIONS, Diabetes, STAGE RENAL-DISEASE, GLOMERULAR HYPERFILTRATION, General Medicine, Kidney disease, Nephrology, Insulin/therapeutic use, Female, medicine.medical_specialty, Renal effects, Diabetes Mellitus, Type 1/drug therapy, Type 1 diabetes mellitus, Renal function, 030209 endocrinology & metabolism, Hypoglycemic Agents/therapeutic use, URIC-ACID, 03 medical and health sciences, Diabetes mellitus, Internal medicine, BASE-LINE CHARACTERISTICS, Internal Medicine, medicine, Hypoglycemic Agents, Humans, COTRANSPORTER 2 INHIBITORS, Diabetic kidney disease, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Type 1 diabetes, Renal Insufficiency, Chronic/drug therapy, business.industry, Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, Type 2 Diabetes Mellitus, nutritional and metabolic diseases, medicine.disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, 3121 General medicine, internal medicine and other clinical medicine, SGLT-2 inhibitor, Adjunctive treatment, Diabetic Nephropathies/drug therapy, Metabolic syndrome, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03aec7f8c17f21dae029eac6142bfa4c
https://biblio.vub.ac.be/vubir/the-nephrological-perspective-on-sglt2-inhibitors-in-type-1-diabetes(a44fea01-9080-41df-b6e2-d8cafdc8e82c).html

10

Dapagliflozin in Patients with Chronic Kidney Disease

المؤلفون: Heerspink, Hiddo J.L., Stefánsson, Bergur V., Correa-Rotter, Ricardo, Chertow, Glenn M., Greene, Tom, Hou, Fan-Fan, Mann, Johannes F.E., McMurray, John J.V., Lindberg, Magnus, Rossing, Peter, Sjöström, C. David, Toto, Roberto D., Langkilde, Anna-Maria, Wheeler, David C., Cruzado, Josep Ma.

المساهمون: Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Groningen Kidney Center (GKC)

المصدر: New England Journal of Medicine, 383(15), 1436-1446. MASSACHUSETTS MEDICAL SOC
Heerspink, H J L, Stefánsson, B V, Correa-Rotter, R, Chertow, G M, Greene, T, Hou, F-F, Mann, J F E, McMurray, J J V, Lindberg, M, Rossing, P, Sjöström, C D, Toto, R D, Langkilde, A-M, Wheeler, D C & DAPA-CKD Trial Committees and Investigators 2020, ' Dapagliflozin in Patients with Chronic Kidney Disease ', The New England Journal of Medicine, vol. 383, no. 15, pp. 1436-1446 . https://doi.org/10.1056/NEJMoa2024816
Dipòsit Digital de la UB
Universidad de Barcelona

مصطلحات موضوعية: Male, Kidney Failure, Chronic/mortality, Benzhydryl Compounds/adverse effects, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Glomerular Filtration Rate/drug effects, law.invention, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Glucosides, law, Diabetic Nephropathies, 030212 general & internal medicine, Dapagliflozin, Kidney, Diabetis, Kidney diseases, Diabetes, EMPAGLIFLOZIN, General Medicine, Middle Aged, medicine.anatomical_structure, Cardiovascular Diseases, Regression Analysis, Female, Glomerular Filtration Rate, medicine.medical_specialty, Finerenone, Renal Insufficiency, Chronic/complications, CARDIOVASCULAR OUTCOMES, Glucosides/adverse effects, 03 medical and health sciences, Internal medicine, Diabetes mellitus, Empagliflozin, medicine, Humans, Benzhydryl compounds, Cardiovascular Diseases/etiology, Benzhydryl Compounds, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Aged, urogenital system, business.industry, Diabetes Mellitus, Type 2/complications, Glucòsids, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, medicine.disease, Diabetes Mellitus, Type 2, chemistry, Diabetic Nephropathies/drug therapy, Kidney Failure, Chronic, Malalties del ronyó, business, Kidney disease

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88a9f07a611f740aec4f679c65611f94
https://research.rug.nl/en/publications/1def9c25-613d-4882-b619-e4099c6307a2

Find this article in full text from ProQuest

تنقيح النتائج